DENOSUMAB TEVA onco 120 mg / 1.7 ml sol inj

7680701320015 CH-70132 M05BX04 07.16.1.

Active substances:

Denosumabum

No images available

Details

Product number
7013201
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
denosumabum 120 mg, natrii acetas trihydricus corresp. natrium 0.49 mg, acidum aceticum glaciale, sorbitolum 79.9 mg, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1.7 ml.

Articles (1)

Denosumab-Teva onco 120 mg / 1.7 ml, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
24/09/2026
Professional SmPC
Français
24/09/2026
Professional SmPC
Italien
24/09/2026

Detailed composition

Substance Quantity Type Category
denosumabum
120.0 MG Substance Wirkstoff (Principe actif)
natrii acetas trihydricus
- Substance HNIDK
natrium
0.49 MG Substance HBESI
acidum aceticum glaciale
- Substance HNIDK
sorbitolum
79.9 MG Substance HBESI
polysorbatum 20
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 210.45
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/03/2026

Authorization holder

Teva Pharma AG

4051 Basel

Authorization information

Swissmedic authorization number
70132
Drug name
Denosumab-Teva onco, Injektionslösung
Galenic form
LSINJ
ATC Code
M05BX04
Authorization status
Z
Dispensation category
A
First authorization
10/12/2025
Authorization expiration date
09/12/2030
IT number
07.16.1.
Domain
Human medicine
Field of application
Knochenmetastasen solider Tumoren; Riesenzelltumoren des Knochens

Packaging details

Description (FR)
DENOSUMAB TEVA onco 120 mg / 1.7 ml sol inj
Description (DE)
DENOSUMAB TEVA onco 120 mg / 1.7 ml Inj Lös
Market launch
01/03/2026
Narcotic (BTM)
No

Other packaging sizes

Buy us a coffee Explore the data